市场调查报告书
商品编码
1466699
心臟标记测试市场:按产品、生物标记、测试类型、疾病 - 全球预测 2024-2030Cardiac Marker Testing Market by Product (Instruments, Reagents & Kits), Biomarker (BNP Or NT-ProBNP, Ceratine Kinase-MB, hs-CRP), Type of Testing, Disease - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
心臟标记检测市场规模预计2023年为51亿美元,预计2024年将达55亿美元,2030年将达86.9亿美元,复合年增长率为7.90%。
心臟标记测试市场包括频谱围绕使用生物标记诊断和管理心血管疾病的医疗技术和服务。心血管疾病的流行和有效诊断的需求导致全世界越来越多地采用心臟标记。心臟标记就地检验的兴起导致心血管疾病筛检显着增加。鼓励早期发现心血管疾病的努力也有助于市场成长。然而,心臟标记测试解决方案产品召回的发生可能会限制市场的采用。此外,与心臟市场测试不准确和特异性有限相关的担忧也对市场成长构成挑战。此外,测试技术的进步和新生物标誌物的整合正在市场上创造有吸引力的机会。消费者对个人化医疗的偏好以及客製化心臟标记测试的引入预计将在未来几年出现显着增长。
主要市场统计 | |
---|---|
基准年[2023] | 51亿美元 |
预测年份 [2024] | 55亿美元 |
预测年份 [2030] | 86.9亿美元 |
复合年增长率(%) | 7.90% |
诊断设备在产品心臟标记检测中的重要性
用于心臟标记检测的诊断设备包括免疫检测装置、护理点(POC)装置和化学冷光分析仪,用于监测和测量与心臟状况相对应的心臟标记。诊断设备以高度准确、及时且使用者友好的方式为心臟测试提供必要的资料评估。试剂/套件是用于确保设备正常运作和成功完成心臟标记测试程序的化学溶液。试剂和套件对于生物检体的反应至关重要,可用于检测各种心臟疾病的心臟标记。
生物标记:在心臟评估中增加肌钙蛋白生物标记的使用
利钠胜肽,例如 N 端脑钠肽原 (NT-proBNP) 和 B 型利钠胜肽(BNP),对于心臟衰竭的评估至关重要,有助于临床医生管理心臟病。 CK-MB 是一种肌酸激酶-MB同功异构酵素,用于检测心肌梗塞周围区域,可用于诊断心臟疾病。高敏感性 CRP (hs-CRP) 检测在识别低恶性发炎以评估心血管疾病和中风风险方面特别有利。肌红蛋白也是重要的心臟生物标记物,是首选,因为它在心肌损伤后很早就达到高峰(1-3小时),主要用于早期检测心肌梗塞。肌钙蛋白检测由于其优异的敏感性和特异性,目前是诊断急性心肌梗塞的治疗方法标准。
测试类型增加了就地检验的采用
临床测试涉及在受控实验室环境(通常在医院或诊断中心内)中分析患者检体,使用先进的设备以实现最大的准确性。心臟标记测试具有高灵敏度和特异性,使其成为实验室环境中需要准确结果时的首选。即时检测 (POCT) 可在患者附近快速提供结果,是一种即时、可操作的工具,对于紧急心臟病至关重要,对心臟病患者的治疗结果具有重大影响,使决策更加容易。
心臟标记检测在心肌梗塞疾病的广泛应用
B型利钠胜肽(BNP)和N末端B型利钠胜肽原(NT-proBNP)测试由于能够快速准确地检测症状而被用作郁血性的主要心臟标记测试。透过肌钙蛋白测试等心臟标记测试可以有效分析心肌梗塞状态,因为心肌损伤后血液中的肌钙蛋白 T 和 I 水平会升高。
区域洞察
在美洲地区,由于技术进步和心血管疾病盛行率上升,心臟标记检测市场正在蓬勃发展。在美国、加拿大和巴西等主要国家,多家当地企业和新兴企业专注于开发和部署经济高效的可携式设备,以进行有效的心臟评估。在欧洲地区,心血管疾病的增加、人口老化和医疗基础设施的建立极大地推动了心臟标记检测市场。中东和非洲地区的心臟标记检测市场受到人们对冠状动脉疾病的认识不断提高和医疗服务扩展的显着影响。由于医疗保健服务的普及和领先企业的大量存在,包括中国、印度和日本在内的亚太地区国家的心臟标记检测市场正在加速成长。政府对医疗保健研究和开发投资的支持增加了心臟检测方法的创新。
FPNV定位矩阵
FPNV定位矩阵对于评估心臟标记检测市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对心臟标记物测试市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.心臟标记检测市场的市场规模和预测是多少?
2.在心臟标记测试市场的预测期内,有哪些产品、细分市场、应用和领域需要考虑投资?
3.心臟标记检测市场的技术趋势和法规结构是什么?
4.心臟标记检测市场主要厂商的市场占有率为何?
5.进入心臟标记检测市场合适的型态和策略手段是什么?
[199 Pages Report] The Cardiac Marker Testing Market size was estimated at USD 5.10 billion in 2023 and expected to reach USD 5.50 billion in 2024, at a CAGR 7.90% to reach USD 8.69 billion by 2030.
Cardiac marker testing market consists of the spectrum of medical technologies and services that revolve around the usage of biomarkers for the diagnosis and management of cardiovascular diseases. The prevalence of cardiovascular diseases and need for effective diagnostics has increased the adoption of cardiac markers worldwide. The rise of point-of-care testing for cardiac markers has significantly increased the screening of cardiovascular diseases. The initiatives encouraging early cardiovascular disease detection have also contributed to market growth. However, the incidences of product recalls of cardiac marker testing solutions may limit its market adoption. The concerns associated with inaccuracy and limited specificity of cardiac market testing are also challenging factors for the market growth. Moreover, the advancements in testing technologies and the integration of new biomarkers are creating attractive opportunities in the market. Increasing consumer preference towards personalized medicine and the introduction of tailored cardiac marker testing are expected to witness significant growth in upcoming years.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 5.10 billion |
Estimated Year [2024] | USD 5.50 billion |
Forecast Year [2030] | USD 8.69 billion |
CAGR (%) | 7.90% |
Product: Significance of diagnostic instruments in cardiac marker testing
Diagnostic instruments in cardiac marker testing includes immunoassay analyzers, point of care (POC) devices, and chemiluminescence analyzers utilized to monitor and measure cardiac markers corresponding to heart conditions. Diagnostic instruments offer essential data evaluation for cardiac tests in a highly accurate, timely, and user-friendly manner. Reagents & kits are chemical solutions used for the proper functioning of instruments and the successful execution of cardiac marker testing procedures. Reagents & kits are vital in reacting with the biological samples, thereby helping to detect cardiac markers for various cardiac conditions.
Biomarker: Rising utilization of Troponin biomarker for cardiac assessment
Natriuretic peptides such as N-terminal proBNP (NT-proBNP) and B-type Natriuretic Peptide (BNP) are essential in the evaluation of heart failure, helping clinicians on cardiac disease management. Though CK-MB, a Creatine Kinase-MB isoenzyme, has been used in periprocedural myocardial infarction testings to better diagnose cardiac condition. High-sensitivity C-reactive protein (hs-CRP) testing is particularly advantageous for identifying low-grade inflammation to assess the risk of cardiovascular disease and stroke. Myoglobin is also a significant cardiac biomarker, favored for its very early peak (1 to 3 hours) following myocardial injury, primarily beneficial in the early detection of myocardial infarction. Troponin tests are currently the standard of care for diagnosing acute myocardial infarction due to their superior sensitivity and specificity.
Type of Testing: Increasing adoption of Point-of-Care testing
Laboratory testing involves analyzing patient samples in controlled lab environments, usually within hospitals or diagnostic centers, and utilizes advanced equipment for utmost accuracy. The high sensitivity and specificity of cardiac marker tests make it the preferred choice when precise results are mandatory in laboratory settings. Point-of-Care Testing (POCT) delivers rapid results in close proximity to the patient's location and are crucial in emergency cardiac conditions, facilitating real-time, actionable decisions that can significantly impact patient outcomes in cardiac disease conditions.
Disease: Extensive applications of cardiac marker testing in myocardial infarction
B-type Natriuretic Peptide (BNP) and N-terminal pro b-type Natriuretic Peptide (NT-proBNP) testing are used as primary cardiac marker tests for congestive heart failure due to their ability to prompt and accurate detection of symptoms. Myocardial infarction condition is effectively analyzed by cardiac marker tests such as troponin tests as troponin T and I levels in the blood increases after heart muscle damage.
Regional Insights
In the Americas region, the cardiac marker testing market has been flourishing with advancements in technology and the escalating prevalence of cardiovascular diseases. Several local companies and start-ups in major countries such as the United States, Canada, and Brazil, have been focusing on developing and introducing cost-effective and portable devices for effective cardiac assessment. In the Europe region, the cardiac marker testing market has been extensively driven by the increasing number of cardiovascular diseases, the aging population, and the well-established healthcare infrastructure. The cardiac marker testing market in the Middle East and Africa has been significantly impacted due to the rising awareness about coronary people diseases and the expansion of healthcare services. Cardiac marker testing market has been growing at an accelerated rate in APAC countries including China, India, and Japan due to the surge in healthcare services and the significant presence of major companies. The government support in terms of investments for healthcare research and development has led to an increase in innovations in cardiac testing methods.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Cardiac Marker Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cardiac Marker Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Cardiac Marker Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Assure Tech (Hangzhou) Co., Ltd., Atlas Medical GmbH, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biomerieux SA, Boditech Med Inc., Charles River Laboratories International, Inc., Cleerly, Inc., Danaher Corporation, DiaSorin S.p.A., Eurofins Scientific SE, F. Hoffmann-La Roche AG, HyTest Ltd., Laboratory Corporation of America Holdings, LightDeck Diagnostics, Merck KGaA, Natera, Inc., PerkinElmer Inc., Qiagen N.V., Quest Diagnostics, QuidelOrtho Corporation, Randox Laboratories Ltd., Sekbio, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Tosoh Corporation.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Cardiac Marker Testing Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cardiac Marker Testing Market?
3. What are the technology trends and regulatory frameworks in the Cardiac Marker Testing Market?
4. What is the market share of the leading vendors in the Cardiac Marker Testing Market?
5. Which modes and strategic moves are suitable for entering the Cardiac Marker Testing Market?